Real-World Analysis Supports Use of Remote Electric Neuromodulation Device for Migraine 

A new peer-reviewed study, published in Frontiers in Pain Research analyzed real world evidence for a remote electric neuromodulation (REN) device (Nerivio; Theranica, Netanya, Israel) for migraine treatment.

In results from the analysis of over 23,000 treatments collected for 19 months, 66.5% of the treatments REN use was standalone. In the efficacy analysis, 32% of participants with episodic migraine (out of 2,514) and 21% of participants with chronic migraine, achieved pain freedom 2 hours post-treatment in most of their treatments, and over 65% experienced sustained pain relief post 2 hours. In approximately 80% of the treatments, no additional prescribed medication was used.

"Migraine, a disabling chronic condition, affects 12% of the population," said Jessica Ailani, MD, director of the MedStar Georgetown Headache Center and professor of Clinical Neurology in the Department of Neurology, and lead author of the study. "While some people with migraine get relief from prescribed or even over-the-counter medications, others do not respond to medications, or cannot tolerate their side effects. There are also people who cannot use medications due to contraindications or being at risk of drug-drug interactions or medication overuse headache. The current analysis of a very large group of patients, over a long period of time and multiple treatments, reinforces that REN provides a safe, efficacious, and stable treatment option for acute treatment of migraine, both as a standalone and as an adjunct therapy. This is a very important component in the migraine therapy toolbox."

In the safety analysis, 0.48%, 59 of the 12,368 participants, reported any device-related adverse events.

The REN device is worn on the upper arm at the onset of a migraine attack controlled by an app on a smartphone. The device alleviates migraine and associated symptoms by triggering an endogenous analgesic mechanism.